The aims of the present study were to analyse the effects of an oral daily dose (10 mg/kg) of the dietary flavonoid quercetin for five weeks in two-kidney, one-clip (2K1C) Goldblatt (GB) hypertensive rats. The evolution of systolic blood pressure was followed by weekly measurements, and morphological variables, proteinuria, plasma nitrates plus nitrites (NO x ) and thiobarbituric acid reactive substances (TBARS), liver oxidative stress markers and endothelial function were determined at the end of the experimental period. Quercetin treatment reduced systolic blood pressure of GB rats, producing no effect in control animals. It also reduced cardiac hypertrophy and proteinuria developed in GB hypertensive rats. Decreased endotheliumdependent relaxation to acetylcholine of aortic rings from GB rats was improved by chronic quercetin treatment, as well as increased endothelium-dependent vasoconstrictor response to acetylcholine and overproduction of TXB 2 by aortic vessels of GB rats, being without effect in normotensive animals. Increased plasma NO x and TBARS, and decreased liver total glutathione (GSH) levels and glutathione peroxidase (GPX) activity were observed in GB hypertensive rats compared to the control animals. Normalisation of plasma NO x and TBARS concentrations and improvement of the antioxidant defences system in liver accompanied the antihypertensive effect of quercetin. We conclude that chronic oral treatment with quercetin shows both antihypertensive and antioxidant effects in this model of renovascular hypertension. (Mol Cell Biochem 270: 147-155, 2005) 
Introduction
Human renovascular disease constitutes a relatively rare form of secondary hypertension, frequently related to the activation of the renin-angiotensin system (RAS), as a result of the fall in the renal blood flow and pressure perfusion produced after renal artery stenosis [1] . The role of the renal vasculature in eliciting such pathology was established by Goldblatt et al. [2] . This group demonstrated in animals that partial obstruction of the renal artery increased mean arterial pres-sure, and developed the experimental model of two-kidney, one-clip Goldblatt (2K1C GB) hypertension, which features human renovascular hypertension.
In the last years, many contributions have evidenced oxidative stress involvement in the development of renovascular hypertension. In this way, Lerman et al. [3] demonstrated that in early renovascular hypertension in pigs, an increase in plasma renin activity and arterial pressure are associated with increased systemic oxidative stress. Moreover, lipid peroxidation is markedly enhanced in hypertensive patients with renovascular disease and is related to activation of the RAS [4] , and excessive oxidative stress is involved, at least in part, in impaired endothelium-dependent function of these patients [5] . In the 2K1C GB hypertensive rat, oxidative stress was increased both systemically and in the kidney, contributing as an important factor to disturb renal function in the clipped kidney [6] .
As the RAS is clearly involved in the development of the pathology, antihypertensive drugs such as angiotensin receptors antagonists or angiotensin converter enzyme (ACE) inhibitors [7] [8] [9] [10] are common therapeutic treatments employed in renovascular hypertension. Anyway, recent works, both in humans and experimental animal models of renovascular hypertension, demonstrate that long-term treatment with antioxidants improve both hypertension and the functional alterations in kidney and heart [6, 11, 12] .
The flavonoid quercetin is one of the most abundant polyphenolic compounds found in the human diet. Our group has reported that chronic daily treatment with quercetin reduced elevated blood pressure, endothelial dysfunction and cardiac and renal hypertrophy in spontaneously hypertensive rats (SHR) [13, 14] , an experimental model of hypertension that reproduces the pathophysiological features of human primary hypertension. Quercetin treatment produced similar effects in hypertension induced by chronic inhibition of nitric oxide synthase by L-nitro-arginine-methyl ester (L-NAME) [15] . In both models, featured by involvement of activation of the RAS in the establishment and maintenance of high blood pressure, the protective effects exerted by quercetin were associated with an improvement of the oxidative status of the hypertensive animals, attributed to the antioxidant properties of the drug. Moreover, there is no information about the effects of quercetin in secondary hypertension such as the 2K1C GB hypertension model in rats.
Therefore, in the present study the main aim was to analyse the effects of chronic administration of an oral daily dose of quercetin (10 mg/kg) on blood pressure, endothelial function and oxidative status in 2K1C GB hypertensive rats.
Materials and methods

Animals and experimental protocol
Twelve-week old male Wistar rats (220-250 g) obtained from the Laboratory Animal Service of the University of Granada (Spain) were used in the study. The experimental protocol was performed in accordance with the European Union guidelines for animal care and protection. All rats were maintained five per cage at a constant temperature (24 ± 1
• C), with a 12-h dark/light cycle. Animals were allowed to adapt to these conditions for a week, before the beginning of the experimental protocol.
The rats were randomly divided into four groups: control (C), quercetin (Q), 2K1C Goldblatt (GB), and 2K1C Goldblatt-quercetin (GBQ). To induce 2K1C renovascular hypertension animals were first anaesthetised with 2.5 mL/kg equitensin (500 mL contain 43% (w/v) chloral hydrate in 81 mL ethanol; 4.86 mg nembutal; 198 mL propylene glycol; 10.63 g MgSO 4 ; distilled water) (i.p.). Afterwards, the left renal artery of 2K1C Goldblatt-groups animals was occluded by a silver clip (0.2 mm internal diameter of the vessel), while the right kidney was not disturbed. Control-groups rats (C and Q) were sham-operated by an incision made in the flank following a 30-s disruption of the renal artery flow. To study the capability of quercetin to revert established hypertension, we waited for three weeks after the clipping, and verified that 2K1C GB animals were hypertensive by measuring systolic blood pressure (SBP), before beginning the oral treatment with our bioflavonoid. Quercetin (10 mg/kg/day) or its vehicle, (methylcellulose 1%), were given by gavage over five weeks. Administration was stopped two days before the end of the experiments, in order to study quercetin long-term effects without the involvement of its acute administration effects. The last day of the experimental period the animals were placed on metabolic cages to collect urine.
Blood pressure measurements
SBP was determined once a week, in the morning, in conscious, pre-warmed, restrained rats by tail-cuff plethysmography (digital pressure meter, LE 5000, Letica S.A., Barcelona, Spain). At least seven determinations were made in every session and the mean of the lowest three values within 5 mm Hg was taken as the systolic blood pressure value.
Samples collection and storage
At the end of the experimental period, animals were anaesthetised with 2.5 mL/kg equitensin (i.p.) and blood was collected from the abdominal aorta. Animals were then sacrificed and thoracic aorta, kidneys, livers and hearts were excised, cleaned and weighed. The atria and the right ventricle were then removed and the remaining left ventricle weighed. The renal, cardiac, and left ventricular weight indices were calculated by dividing the kidney, heart and left ventricle weight by the body weight. Plasma was obtained by blood centrifugation at 2000g for 15 min, aliquoted and frozen. All biological samples were stored at −80
• C until analysis.
Plasma and urine analytical procedures
Proteinuria was determined according to the method of Bradford [16] , using bovine serum albumin as standard, and the results were expressed as mg of protein excreted per 100 g of rat during 24 h. Plasma thiobarbituric acid reactive substances (TBARS) content and the stable NO metabolites, nitrites plus nitrates (NO x ) concentration were evaluated as previously described [14, 15] .
Determination of liver total glutathione (GSH) content and GSH-related enzymes activities
Organ samples were deproteinized by homogenisation with 5% trichloroacetic acid. Homogenates were centrifuged at 4000g for 10 min and an aliquot of the supernatant was taken for the measurement of GSH using the 5,5 -dithio-bis(2-nitrobenzoic acid) recycling assay described by Anderson [17] . Data were expressed as nmol GSH/g weight of tissue.
GSH-related enzymes activity determinations were performed as previously described [14, 15] .
In vitro vascular function
Three-mm ring segments of the descending thoracic aorta were dissected and mounted in individual organ chambers filled with Krebs buffer of the following composition (mM): NaCl 118, KCl 4.75, NaHCO 3 25, MgSO 4 1.2, CaCl 2 2, KH 2 PO 4 1.2, glucose 11. The solution was continuously gassed with a 95% O 2 and 5% CO 2 mixture, and maintained at 37
• C. Rings were stretched to 2 g of resting tension by mean of two L-shaped stainless-steel wires, which were inserted into the lumen and attached to the chamber and to an isometric force-displacement transducer (Letigraph, model 2000, Letica S.A., Barcelona, Spain), as previously described [13] . After equilibration, concentrationresponse curves to noradrenaline (10 −9 to 10 −6 M), or KCl (8-80 mM) were constructed by cumulative addition of the drugs in endothelium-denuded rings. The concentrationrelaxation response curves to acetylcholine (10 −9 to 10 −4 M) were performed in intact rings pre-contracted by 10 −6 M noradrenaline. The relaxant responses to sodium nitroprusside (10 −9 to 10 −5 M) were studied in the dark in endotheliumdenuded vessels pre-contracted by 10 −6 M noradrenaline. Endothelium-dependent contractions to acetylcholine (ACh) were tested in rings that were previously stimulated with 80 mM KCl. After washing with Krebs solution, rings were incubated for 30 min with or without SQ-29,548 (10 −7 M) and with L-NAME (10 −4 M), and afterwards ACh was added in a cumulative fashion (10 −8 to 10 −4 M). Concentration response curves to KCl were expressed as g of force, while those of noradrenaline were expressed as a percentage of the response to 80 mM KCl. Relaxant responses to acetylcholine and sodium nitroprusside were expressed as a percentage of pre-contraction induced by noradrenaline. The contractile responses to ACh were expressed as a percentage of the response to KCl.
Thromboxane B 2 production in aortic rings
To determine the production of TXB 2 , rat aortic rings with endothelium obtained from animals of the different experimental groups were incubated for 20 min at 37
• C in a 95% O 2 to 5% CO 2 gas mixture, in 2 mL of Krebs' solution containing L-NAME (10 −4 M). Rings were then stimulated with ACh (10 −4 M) for ten min. At the end of this incubation period, 500 µL of the medium were collected and TXB 2 produced was measured by mean of an enzyme inmmunoassay kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) [18] .
Drugs
Quercetin dihydrate and all the other drugs and chemical used were obtained from Sigma (Alcobendas, Madrid, Spain), except SQ-29,548, which was purchased from ICN (Biomedicals, Inc., Barcelona, Spain).
Statistical analysis
Results are expressed as mean ± standard error of mean (S.E.M.) of measurements. For statistical analysis, we used one-way analysis of variance followed by Bonferroni's multiple comparisons test. For all comparisons, differences were considered significant at a value of p < 0.05. Concentration -response curves were fitted to the logistic equation:
, where E max is the maximal effect, k is a factor which represents the slope of the curve and pD 2 is the drug concentration exhibiting 50% of the E max expressed as negative log molar.
Results
Blood pressure, body weight, cardiac and renal indices and proteinuria
SBP values before clipping the left renal artery were about 142-149 mm Hg. Partial occlusion of the renal artery produced a progressive increase in SBP of GB rats and hypertension was stable three weeks after clipping the renal artery (SBP values of 179-184 mm Hg). The present study shows for the first time that daily oral administration of 10 mg/kg quercetin for five weeks reduced SBP ( p < 0.05) in hypertensive GB rats since the second week of treatment ( Fig. 1) , reaching a maximal fall of about 50% at the end of the experimental period. No change in SBP was observed in quercetintreated control rats.
Values of body weight and cardiac and renal indices are shown in Table 1 . At the end of the experimental period, animals of the GB group showed increased cardiac (∼20%), left ventricular (∼25%) and contralateral clipped kidney (∼26%) weight indices, as compared to the control group animals ( p < 0.05), while stenotic kidney weight index of GB animals decreased (∼28%). In the GB treated with quercetin group, cardiac and left ventricular indices were reduced as compared to the GB group ( p < 0.05). Anyway, quercetin treatment had no effect on the contralateral kidney hypertrophy.
Proteinuria was markedly greater ( p < 0.05) in the GB animals compared to the controls. Although quercetin chronic treatment did not improve renal hypertrophy, it contributed to ameliorate renal damage, as proteinuria was significantly reduced in the GBQ group (Fig. 2) .
Plasma variables and hepatic GSH content and GSH-related enzyme activities
In our study plasma TBARS concentration and NO x levels were increased in GB rats ( p < 0.05) as compared to the control group (Fig. 3) . GB hypertensive animals chronically treated with quercetin showed lower plasma MDA and NO x concentrations ( p < 0.05), in the range of those shown by animals of control groups (Fig. 3) . Furthermore, the hepatic GSH content and glutathione peroxidase (GPX) activity were decreased in GB animals ( p < 0.05) compared to the control animals ( Figs. 4A and 4B ). In the GB animals treated with quercetin (GBQ), GPX activity reached values own to the control rats (Figs. 4A and 4B ).
Ex vivo vascular reactivity of aortic rings
In aortic rings no differences were observed among groups in the endothelium-independent vasodilator responses to the NO donor sodium nitroprusside or to the vasoconstrictor responses induced by noradrenaline or KCl (Table 2) . However, aortic rings from GB animals showed strongly reduced endothelium-dependent vasodilator responses to acetylcholine in arteries stimulated by noradrenaline as compared to those of the control rats ( p < 0.05) (Fig. 5) . The aortic rings obtained from GB hypertensive animals treated with quercetin showed a significant increase in vasodilatation induced by acetylcholine as compared to the animals from the GB group ( p < 0.05) (Fig. 5) . We have also found that, in the presence of L-NAME (10 −4 M), the vasoconstrictor response to acetylcholine (ACh) in endothelium-intact aortic rings from GB rats was significantly increased as compared to that of the control group animals (Fig. 6A ). Co-incubation Values are expressed as mean ± S.E.M. E max (maximal effect) for noradrenaline and KCl are expressed as g of contraction per mg of aortic tissue, and for sodium nitroprusside (SNP) as a percentage of relaxation of the pre-contraction with noradrenaline per mg of aortic tissue. Potency (−log EC 50 ) is the drug concentration (M) exhibiting 50% of the E max expressed as negative log molar. Potency (−log IC 50 ) is the drug concentration (M) relaxing 50% of the pre-contraction with noradrenaline expressed as negative log molar. Experimental groups control vehicle (C); control quercetin (CQ); 2K1C Goldblatt hypertensive vehicle (GB); and 2K1C Goldblatt hypertensive quercetin (GBQ). of the rings with the antagonist of prostanoid thromboxaneendoperoxide receptors SQ-29,548 almost abolished these contractions (data not shown). In fact, we have also observed that TXB 2 production stimulated by ACh from aortic rings of GB rats was increased ( p < 0.05) (Fig. 6B) . Chronic orally treatment of GB rats with quercetin reduced ( p < 0.05) the endothelium-dependent vasoconstrictor response to ACh and the aortic TXB 2 release (Fig. 6 ).
Discussion
2K1C GB hypertension is an experimental model that reproduces in animals human renovascular hypertension, a secondary form of hypertension related to the activation of the RAS, and in which oxidative stress is clearly involved [1] [2] [3] [4] [5] [6] .
The present results shows for the first time that chronic orally treatment of 2K1C GB hypertensive rats with 10 mg/kg/day of the antioxidant dietary flavonoid quercetin reduced SBP, improved aortic endothelium-dependent relaxation to ACh, and decreased cardiac hypertrophy and proteinuria. These effects were accompanied by increase of liver antioxidant defences and decreased lipid peroxidation, and diminished vascular production of the vasoconstrictor prostanoid TXA 2 . Quercetin interferes in the RAS, as it inhibits angiotensinconverting enzyme and neutral endopeptidase activities in vivo [19, 20] . Such effects would reduce angiotensin II production and facilitate auricular natriuretic peptides accumulation. This activity of quercetin could contribute to explain its hypotensive effect in the 2K1C GB hypertensive animals. Anyway, other mechanisms must be involved in this effect, as quercetin has also shown to be effective in lowering blood pressure in DOCA-salt [21, 22] and in Dahl salt-sensitive hypertensive rats [23] , two experimental models associated with low plasma renin activity [24, 25] . In fact, in Dahl salt-sensitive hypertensive rats, this antihypertensive effect of quercetin is accompanied by a reduced expression of epithelial Na + channel (ENaC) contributing to Na + reabsorption in the kidney, suggesting that quercetin would reduce hypertension caused by high-salt-diet via reduction of ENaC expression [23] .
Sustained high blood pressure is one of the most powerful determinants of cardiac and renal hypertrophy. In our study, the GB rats treated with quercetin showed reduced cardiac and left ventricular indices as compared to the GB group, reaching values similar to those of control rats, while reduction of SBP, although significant, was far from normal values. This fact suggests that quercetin possesses antihypertrophic properties unrelated to its antihypertensive effect. Several studies on isolated vascular smooth muscle cell have shown that quercetin inhibits proliferation, hypertrophy and the migration from the media into the intima, and blocks their stimulation by serum and growth factors [26] [27] [28] . In vivo, quercetin reduced the vascular remodeling associated with elevated blood pressure in spontaneously hypertensive rats [13] . The inhibitory effects of quercetin on DNA synthesis of TNF-α-stimulated vascular smooth muscle cells appear to be related to reduced ERK 1/2 activity [28] , a kinase playing a major role in cell proliferation and differentiation. In contrast, down-regulation of the JNK pathway was involved in inhibition of hypertrophy induced by quercetin in cells stimulated by angiotensin II [27] . Quercetin also inhibits cultured neonatal rat cardiomyocytes hypertrophy induced by angiotensin II and this effect seem to be related to its inhibitory effect on PKC and tyrosine protein kinase [29] , and it also prevents cardiac remodeling in mice left ventricle [30] . Long-term oral administration of this flavonoid in other experimental models of hypertension also featured by cardiac, left ventricular and renal hypertrophy significantly reduced these organs hypertrophy accompanying an interesting antihypertensive effect [13, 15, 21] . Although quercetin chronic treatment did not improve renal hypertrophy in renovascular hypertension, it contributed to ameliorate renal damage in this experimental model, as proteinuria was significantly reduced in the GBQ group.
The present results show that renovascular hypertension is accompanied of vascular endothelial dysfunction as assessed by a reduced endothelium-dependent relaxation to ACh in aorta of GB rats. Previous studies have shown a diminished endothelium-dependent vasodilator capability in resistance arteries [31] [32] [33] . Quercetin treatment improved aortic endothelial function in the GB rats. Endothelial dysfunction is related to a decrease in nitric oxide bio-availability. In the present results, plasma levels of NO x were slightly but significantly increased in GB hypertensive rats compared to the control animals. This result could seem surprising, as endothelial-dependent relaxation is clearly diminished in aorta of GB rats. Anyway, many authors have reported an increase in plasma basal NO x concentration of SHR in relation to the levels found in WKY [34] [35] [36] . This increase could be due to the elevation of activity and protein expression of inducible nitric oxide synthase (iNOS), as shown in other experimental models of hypertension. In fact, oxidative stress can induce transcription factor nuclear factor kappa B responsive genes such as iNOS, which play an important defensive role against oxidative stress [37] . Quercetin chronic treatment not only reduces elevated SBP in GB animals, it also improved endothelial-dependent relaxation to ACh, a function depending on eNOS, and reestablished plasma NO x concentration. This flavonol has shown nitric oxide scavenging properties but it has especially been described for NO protecting effects leading to increase its bioactivity in vascular smooth muscle [38] . These last properties are most patent in oxidative stress conditions, as under increased superoxide anion concentrations, quercetin acts as a better scavenger of this radical specie than of NO [38] .
The renovascular model of hypertension is characterised by an increased oxidative stress status [3] , which is involved in endothelial dysfunction [5] . Oxidant stress is evidenced by significantly higher TBARS levels in plasma of GB animals compared to the control normotensive rats, reflecting increased lipid peroxidation, and by alterations in liver total GSH content and GPX activity. In this way, decrease in total hepatic GSH content of GB hypertensive rats is consequent to the important oxidative damage caused by oxygen radicals formed in liver after clipping the renal artery [3] . In the present study we have also found a diminished liver GPX activity in GB rats, another sign indicative of oxidative stress, as it leads to increased cellular accumulation of ROS and lipid peroxidation, detected as plasma accumulation of TBARS. A consistent finding concerning GSH cycle alterations in different hypertension models is a decreased hepatic GPX activity [14, 22, 39] . Quercetin chronic treatment reduced liver total GSH content of GB rats but also of control animals. This effect is not surprising as quercetin forms conjugates with GSH, triggering depletion of this endogenous antioxidant [40] . Long treatment with this flavonoid also resulted in the increase in liver GPX activity and plasma reduction of TBARS in GB rats, effects that should be attributed to its antioxidant properties. The flavonoid quercetin exerts antioxidant properties in vitro, by inhibiting xanthine oxidase activity [41] and scavenging radical species such as superoxide anion, hydroxyl radical, and peroxynitrite [42] . When administered orally in vivo, quercetin is biotransformed into metabolites that retain its antioxidant properties [43] . The protective effects exerted by quercetin in the SHR, nitric oxide-deficient and mineralocorticoid hypertension models, were associated with an improvement of the oxidative status of the hypertensive animals, attributed to the antioxidant properties of the drug [14, 15, 22] . In the renovascular experimental model, the antioxidant properties of quercetin seem to be also involved in the improvement of the antioxidant defences in the GB hypertensive animals.
ACh produces a vasoconstrictor response that disappears in the absence of endothelium, thus ruling out the possibility of a direct vasoconstrictor action on the vascular smooth muscle cells. The antagonist of prostanoid thromboxaneendoperoxide receptors SQ-29,548 almost abolished these contractions, suggesting that they are mediated by a prostanoid. This effect has been attributed to the increase in TXA 2 formation and release from endothelial cells of aortic rings in this experimental hypertension model [44] . This vasoconstrictor prostanoid plays an important role in the maintenance of GB hypertension, as chronic administration of TXA 2 /PGH 2 receptor antagonists reduced blood pressure of GB animals [45] [46] [47] . Our present results on chronic orally administration of quercetin to GB rats shows that this treatment reduced both the endothelium-dependent vasoconstrictor response to ACh and the aortic TXB 2 release, effects which would contribute to lower blood pressure.
In conclusion, the present data demonstrate that chronic quercetin treatment of renovascular hypertensive rats reduces hypertension, cardiac hypertrophy and proteinuria and improved endothelium-dependent function in renovascular GB rats. These effects were associated to the improvement of antioxidant defences and a diminished vascular production of the vasoconstrictor prostanoid TXA 2 .
